文献速递炎症性肠病

婴儿乌司奴单抗清除率、感染风险及孕期暴露后发育情况

Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-01-24

该前瞻性研究纳入丹麦和荷兰19家医院的76例妊娠炎症性肠病患者,共78例活产婴儿,评估乌司奴单抗在婴儿体内的清除、感染风险及发育里程碑。婴儿出生时药物浓度中位数为母体的2.18倍,平均清除时间6.7个月;6月龄时1/4婴儿浓度极低(中位0.015 μg/mL)。未观察到不良妊娠结局、感染或发育异常信号,婴儿药物浓度与感染风险无关。

要点

  • 婴儿出生时乌司奴单抗浓度中位数为母体的2.18倍,平均清除时间6.7个月。
  • 6月龄时1/4婴儿浓度极低(中位0.015 μg/mL,范围0.005-0.12 μg/mL)。
  • 婴儿药物浓度与第一年感染风险无关,未观察到发育异常信号。

核心结论

  • 孕期宫内暴露于乌司奴单抗后,未观察到妊娠结局、感染或第一年发育里程碑方面的不良信号。
  • 婴儿乌司奴单抗浓度与感染风险无关。
  • 基于乌司奴单抗清除特征,从6月龄起接种减毒活疫苗似乎风险较低。

研究设计与样本

  • 前瞻性研究,2018年至2022年从丹麦和荷兰19家医院招募妊娠炎症性肠病患者。
  • 共76例妊娠,78例活产婴儿。
  • 评估导致住院或使用抗生素的婴儿感染及发育里程碑。
  • 分娩时及特定时间点测量血清乌司奴单抗浓度,采用非线性回归分析估计清除率。

主要发现

  • 不良妊娠结局风险低,发育里程碑正常。
  • 出生时婴儿与母亲乌司奴单抗浓度比值中位数为2.18(95%CI 1.69-2.81)。
  • 婴儿平均清除时间为6.7个月(95%CI 6.1-7.3个月)。
  • 6月龄时4例婴儿中有1例浓度极低,中位0.015 μg/mL(范围0.005-0.12 μg/mL)。
  • 第一年有感染与无感染的婴儿中位乌司奴单抗浓度无差异:有感染2.8 μg/mL(范围0.4-6.9)vs 无感染3.1 μg/mL(范围0.7-11.0),P=0.41。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence on ustekinumab safety in pregnancy is gradually expanding, but its clearance in the postnatal period is unknown. The aim of this study was to investigate ustekinumab concentrations in umbilical cord blood and rates of clearance after birth, as well as how these correlate with maternal drug concentrations, risk of infection, and developmental milestones during the first year of life. METHODS: Pregnant women with inflammatory bowel disease were prospectively recruited from 19 hospitals in Denmark and the Netherlands between 2018 and 2022. Infant infections leading to hospitalization/antibiotics and developmental milestones were assessed. Serum ustekinumab concentrations were measured at delivery and specific time points. Nonlinear regression analysis was applied to estimate clearance. RESULTS: In 78 live-born infants from 76 pregnancies, we observed a low risk of adverse pregnancy outcomes and normal developmental milestones. At birth, the median infant-mother ustekinumab ratio was 2.18 (95% confidence interval, 1.69-2.81). Mean time to infant clearance was 6.7 months (95% confidence interval, 6.1-7.3 months). One in 4 infants at 6 months had an extremely low median concentration of 0.015 μg/mL (range 0.005-0.12 μg/mL). No variation in median ustekinumab concentration was noted between infants with (2.8 [range 0.4-6.9] μg/mL) and without (3.1 [range 0.7-11.0] μg/mL) infections during the first year of life (P = .41). CONCLUSIONS: No adverse signals after intrauterine exposure to ustekinumab were observed with respect to pregnancy outcome, infections, or developmental milestones during the first year of life. Infant ustekinumab concentration was not associated with risk of infections. With the ustekinumab clearance profile, live attenuated vaccination from 6 months of age seems of low risk.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Julsgaard M, Wieringa JW, Baunwall SMD, et al. Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy. Clin Gastroenterol Hepatol. 2024. PMID: 38278191. doi:10.1016/j.cgh.2024.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。